You are here

Adderall Sales in Canada Suspended, FDA Responds

ROCKVILLE, MD -- February 10, 2005 -- FDA is aware of Health Canada’s decision to suspend sales, but not revoke the approval in Canada, of the drug Adderall as a treatment for Attention Deficit and Hyperactivity Disorder (ADHD). FDA has been in close consultation with the Canadian authorities regarding the basis for their action. FDA does not feel that any immediate changes are warranted in the FDA labeling or approved use of this drug based upon its preliminary understanding of Health Canada’s analyses of adverse event reports and FDA’s own knowledge and assessment of the reports received by the agency.

FDA is issuing a Public Health Advisory and information sheets on its website at www.fda.gov in order to address questions that may arise from the Canadian announcement and to provide up-to-date information about Adderall’s safety profile.

Patients using Adderall (or parents of children on the drug) who have questions about this medication should consult their physicians before making any alterations to their therapy.

As with any drug, FDA will continue to carefully assess any new data that emerges which significantly affects the safety profile of this drug and will take immediate, appropriate action to promote the public health and make the public aware of its findings.

To view the Canadian advisory, click here: http://www.hc-sc.gc.ca/english/protection/warnings/2005/2005_01.html.

Source: The Food and Drug Administration

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications